Next Phase Newsletter

Headquartered in Hong Kong, with offices in the US, an international asset management hub is actively investing in technology and healthcare. The firm focuses on early-stage and expansion opportunities, and can invest in both equity and debt. It typically participates in Series A to Series B rounds, with check sizes ranging from $1M to $50M. The firm primarily focuses on the US and Europe and is particularly interested in companies aiming to expand into Asian markets. The firm has partnerships with manufacturing, CRO, and distribution channels in China and is open to leveraging these resources for its portfolio companies. The firm is open to both leading and co-investing. 
 
The firm primarily considers opportunities in therapeutics, medical devices, and healthtech. For therapeutics, the firm prefers companies/assets in the post-IND phase or those generating clinical data. For medical devices, the firm is open to all classes: for Class I devices, the firm prefers products that have already received approval; for Class II and Class III devices, it prefers mid to late-stage products with CE/FDA approval. For healthtech companies, the firm prefers those already generating revenue. The firm focuses on indications with large market potential, particularly in the US and China. 
 
The firm does not have specific requirements for a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A life-sciences focused venture capital firm is currently making investments into US-based companies. The firm primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment.  The firm could make as many as 3 new investments over the next 6-9 months. 
 
The firm is looking for U.S. companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and digital health. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement. 
 
The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm that manages innovative venture capital funds and is based in San Diego, California. The firm invests in early, growth, and expansion-stage technology and life science companies. The firm principally invests in early and growth-stage investments in Series A, B, and C preferred equity rounds with other top-tier institutional and corporate investors. The investment size is variable and dependent on the company’s capitalization plan and future capital requirements. The firm currently focuses its investment activities in parts of the western USA that are under-served by venture capital. The firm is actively seeking institutional investment limited partners and new investment opportunities. 
 
In the Life Sciences area, the firm seeks to invest in medical device, product, diagnostics, specialty pharma, and healthcare IT.  The firm is opportunistic in terms of sub-sectors and indications.  The firm generally seeks clinical stage therapeutics that are at least Phase II, and diagnostics and medical devices that are very close to or with FDA approval. 
 
The firm is led by a seasoned VC with a track record of investing.  The firm generally co-invests with other top-tier institutional and corporate investors, and will work with companies to help them organize an investment syndicate. The firm seeks investment opportunities in rapidly growing companies with world-class products and solutions that address major market needs; along with talented leadership, management teams, and boards with deep industry experience and track records of success. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global healthcare company that specializes in plasma-related medicines has a global presence in the US, Europe, and Asia. The firm’s external innovation arm seeks to partner with early-stage companies developing therapeutic assets that strategically align with the firm’s focus areas. The group is science-focused and strategically invests in the corporation’s long-term goal of developing pipelines in biotech beyond plasma-related medicines. The group primarily makes equity investments but is open to different structures such as co-development, licensing, and potentially acquisitions. The group often co-invests/syndicates with other investors and typically does not require a board seat. The group is open to considering global opportunities with a focus on the US and Europe. 

The group is focused on therapeutics and is not interested in diagnostics or other sectors. The group seeks strategic alignments within the parent company’s pharma business, which focuses on immunology, infectious diseases, pulmonology, and hematology. The group is particularly interested in biologics due to their expertise in this class of assets and is open to considering other classes of assets such as small molecules, cell and gene therapy (platform), mRNA therapies, etc. The group is also open to considering orphan diseases as well. In terms of phases of development, the group is interested in pre-clinical to early clinical phases. 

The group does not have any specific requirements for the company’s management team. The group acts as an active investor and is open to working with portfolio companies with their in-house expertise and leveraging the firm’s manufacturing capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A digital healthcare-focused seed fund that was founded in 2015 typically acts as the lead investor in a priced equity round. The firm’s team is made up of three partners and has collectively invested in more than a dozen digital health companies as individual investors. The fund currently focuses on opportunities across the United States, with a target investment in the $500,000 range. 

The firm seeks to fund companies working in the digital health space, including health data management systems, patient-physician interface, cloud computing, and software-enabled devices. 

The firm looks for teams that have some healthcare experience in senior management. The firm prefers a strong founding team, possessing varied skills that include technical expertise, sales, operational and marketing experience in senior leadership. After investment, the firm actively advise portfolio companies in various ways, including helping with introductions to health system customers, building teams and advising on operations and management. As such the firm will usually hold a seat on the board along with the founders. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A cross-border venture capital firm founded in 2014 and is headquartered in Tokyo, Japan, with USA offices in Cambridge, MA and Seattle, WA is currently investing from their second fund of $95M. Its LPs includes some of the largest Japanese pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies with the goal of bringing them to a more mature stage of development. Typically, the firm makes an initial investment ranging from under $1M to $3-6M dependent on the company’s stage of development. The firm can allocate up to $16M over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide. 

The firm only invests in therapeutics and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area. 

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the UK and founded in 2020 invests in women-led businesses in biosciences. The firm centers on a USD $100M fund raised as two rounds, the first having $30M to invest. The funds are focused health-tech ventures, with the main goal to hold investors and businesses accountable for diversity in management and teams. Check sizes can range between USD $350k-1.5M. The firm engages with companies in early stages and can also help identify ventures that they can back at a later stage. If the firm decides to not move forward with an investment, they are happy to support and utilize their global network to provide warm introductions to other investors and KOLs they have relationships with. The firm acts as a co-investor and will not lead. The firm is open to meeting companies based in the US, UK, Europe, Australia, and Asia. 

The firm does not invest in therapeutics and direct consumer marketing. The firm is interested in heavy sciences that have a technical element, including medical devices, diagnostics, and digital health. They may look at platforms that help identify therapeutics but will not look at pure therapeutics. The firm is indication-agnostic. The firm would like to see companies with a protectable IP. 

The firm does not require founders to be female, but require female management team members. The firm typically do not sit on board or observer seats but may if a company were to request. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.